Publications by authors named "N G Gavalas"
We previously showed that ERCC1 19007 C>T polymorphism was associated with cancer-specific survival (CSS) after platinum-based chemotherapy in patients with advanced urothelial cancer (aUC). We aimed to confirm this association in a different cohort of patients. Genotyping of the 19007C>T polymorphism was carried out by polymerase chain reaction (PCR) amplification and restriction fragment length polymorphism (RFLP) in 98 aUC patients, treated with platinum-based chemotherapy.
View Article and Find Full Text PDFArticle Synopsis
- Members of the α-thymosin family, particularly prothymosin α (proTα) and its peptide proTα(100-109), have been shown to boost T helper type 1 (Th1) immune responses and enhance antitumor T cell activity both in the lab and in living organisms.
- Safety assessments in silico, in human cells, and in healthy mice indicated that proTα and proTα(100-109) are likely non-toxic and do not promote harmful effects, similar to the established safety of thymosin alpha 1 (Tα1).
- Overall, the research suggests that proTα and proTα(100-109) are safe at high concentrations and maintain
Background: Overexpression of c-Myc is commonly seen in human ovarian cancers, and this could be a potentially novel therapeutic target for this disease. JQ1, a selective small-molecule BET (Bromodomain and extraterminal domain family) bromodomain (BRDs) inhibitor, has been found to suppress tumour progression in several cancer cell types.
Results: Using a panel of ovarian cancer cell lines and primary cell cultures from human ovarian cancer ascites, we demonstrated that JQ1 significantly suppressed cell proliferation and induced apoptosis in an ovarian cancer cell by targeting BRD4 and c-Μyc.
Berberine Effects on NFκB, HIF1A and NFE2L2/AP-1 Pathways in HeLa Cells.
Anticancer Agents Med Chem
February 2020
Background: Berberine has multitudinous anti-cancer stem cells effects making it a highly promising candidate substance for the next-generation cancer therapy. However, berberine modes of action predispose it to significant side-effects that probably limit its clinical testing and application.
Materials And Methods: HeLa cells were treated with two concentrations of berberine (30 and 100 µM) for 24 hours to assess the functioning of the NFE2L2/AP-1, NFκB and HIF1A pathways using 22 RNAs expression qPCR-based analysis.